Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18666146 | 1.00 | ADRA2C (0.54) | ADRA2CL3MBTL1GAAPOLBTDP1 | |
| SCHEMBL18666199 | 0.92 | DEGS1 (0.49) | ADRA2CL3MBTL1GAAPOLBTDP1 | |
| SCHEMBL18666157 | 0.91 | ALDH1A1 (0.48) | ADRA2CL3MBTL1GAAPOLBMEN1 | |
| SCHEMBL18666149 | 0.91 | ALDH1A1 (0.55) | POLBTDP1MEN1KMT2ALMNA | |
| SCHEMBL18666150 | 0.90 | MTNR1B (0.47) | ADRA2CL3MBTL1GAAPPARGALDH1A1 | |
| SCHEMBL21675770 | 0.89 | ALDH1A1 (0.45) | ADRA2CL3MBTL1GAAPOLBTDP1 | |
| SCHEMBL18666151 | 0.89 | MTNR1B (0.63) | POLBTDP1MEN1KMT2ALMNA | |
| SCHEMBL30567101 | 0.89 | MTNR1B (0.63) | POLBTDP1MEN1KMT2ALMNA | |
| SCHEMBL25387279 | 0.89 | PPARG (0.55) | ADRA2CL3MBTL1GAAPOLBTDP1 | |
| SCHEMBL30668811 | 0.89 | PPARG (0.55) | ADRA2CL3MBTL1GAAPOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119326903-A | Combined use of PCNA inhibitor and PARP1 inhibitor | 兰州大学 | 2025-01-21 | — | — | CN | claimed |
| CN-117069838-B | Use of AOH1160 and antibodies in combination for the treatment of cancer | 广东赛尔生物科技有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-117069838-A | Use of AOH1160 and antibodies in combination for the treatment of cancer | 广东赛尔生物科技有限公司 | 2023-11-17 | — | — | CN | claimed |
| EP-3349754-B9 | PCNA INHIBITORS | HOPE CITY (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12435030-B2 | PCNA inhibitors | CITY OF HOPE (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4616910-A2 | PCNA INHIBITORS | City of Hope (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-3349754-B1 | PCNA INHIBITORS | HOPE CITY (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-120192304-A | PCNA inhibitor and application thereof | 上海吉倍生物技术有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250171404-A1 | PCNA INHIBITORS AND USES THEREOF | UNITED STATES GOVERNMENT | 2025-05-29 | — | — | US | disclosed |
| CN-119326903-A | Combined use of PCNA inhibitor and PARP1 inhibitor | 兰州大学 | 2025-01-21 | — | — | CN | disclosed |
| EP-4490142-A2 | PCNA INHIBITORS AND USES THEREOF | City of Hope (US) | 2025-01-15 | — | — | EP | disclosed |
| CN-117069838-B | Use of AOH1160 and antibodies in combination for the treatment of cancer | 广东赛尔生物科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117069838-B | Use of AOH1160 and antibodies in combination for the treatment of cancer | 广东赛尔生物科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117069838-B | Use of AOH1160 and antibodies in combination for the treatment of cancer | 广东赛尔生物科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117069838-A | Use of AOH1160 and antibodies in combination for the treatment of cancer | 广东赛尔生物科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117069838-A | Use of AOH1160 and antibodies in combination for the treatment of cancer | 广东赛尔生物科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117069838-A | Use of AOH1160 and antibodies in combination for the treatment of cancer | 广东赛尔生物科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2023172880-A2 | PCNA INHIBITORS AND USES THEREOF | CITY OF HOPE (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20220340516-A1 | PCNA INHIBITORS | CITY OF HOPE | 2022-10-27 | — | — | US | disclosed |
| US-11345656-B2 | PCNA inhibitors | CITY OF HOPE (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435030-B2 | PCNA inhibitors | PCNA, MKI67, PCLAF | ADRA2C 4716/4885L3MBTL1 1829/4885GAA 2778/4885 |
| US-11345656-B2 | PCNA inhibitors | PCNA, MKI67, PCLAF | ADRA2C 4716/4885L3MBTL1 1829/4885GAA 2778/4885 |
| US-20220340516-A1 | PCNA INHIBITORS | PCNA, MKI67, PCLAF | ADRA2C 4716/4885L3MBTL1 1829/4885GAA 2778/4885 |
| US-20250171404-A1 | PCNA INHIBITORS AND USES THEREOF | PCNA, MKI67, PCLAF | ADRA2C 4795/4885L3MBTL1 1817/4885GAA 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.